יחס שווי פעילות לרווח לפני ריבית, מסים ופחת: Actuate Therapeutics, Inc. (ACTU)
Actuate Therapeutics, Inc. (ACTU) generates revenue by attracting investments to create cutting-edge drugs for combating resistant tumors. The company is developing specific GSK-3beta inhibitors, which offer the advantages of minimal toxic impact and patent protection. The share price retrospective on GURU.Markets shows an EV/EBITDA of 0.00, while the business remains exposed to high risks due to its concentration on a single drug during trials.
פילוחי מדדים ואנליטיקה של חברת Actuate Therapeutics (ACTU)
The fundamental attractiveness of Actuate Therapeutics, Inc. (ACTU) is determined through the prism of business value relative to its operational efficiency. This Enterprise Value to EBITDA ratio on GURU.Markets compares market capitalization, adjusted for debt, against EBITDA to identify the asset's true floor. The metric measures the investment payback period by excluding the impact of taxes and depreciation. For Actuate Therapeutics, Inc. (ACTU) and its promising oncology pipeline, this indicator confirms the market's vote of confidence in future cash flows.
